NCT05679687 - ThisCART19A Bridging to alloHSCT for R/R B-ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

CARRefractory Acute Lymphoblastic LeukemiaRelapsed Adult ALL

Interventions

DRUG

Treatment

In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou